Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Ocular Therapeutix Inc Saw its Share Price Jump Today

What happened

Ocular Therapeutix (NASDAQ: OCUL  ) is up almost 12% at 3:21 p.m. EDT Thursday after the company reported positive patient experience for its eye insert, Dextenza, Wednesday morning. That's on top of a 6.6% jump Wednesday.

So what

The survey asked 25 patients from the company's phase 3 trial testing Dextenza as a treatment for post-surgical ocular pain and inflammation about their experience with the product. Dextenza is an insert that releases a corticosteroid, dexamethasone, which is typically administered through eye drops. The insert is absorbed by the body so it doesn't need to be removed at the end of the treatment.

A closeup of an eye.

Image source: Getty Images.

In the retrospective study, 96% of patients said the insert was extremely convenient or very convenient compared to topical eye drops, which have to be tapered on a schedule. Also, 92% of patients said they would recommend Dextenza to friends or family members.

The FDA has a goal to make a decision about the potential approval of Dextenza by July 19. The agency rejected Ocular's application last year because of manufacturing issues.

Now what

This data isn't going to determine whether Ocular Therapeutix can get Dextenza approved by the Food and Drug Administration, but the fact that patients seems to like the treatment is good news for potential sales. Patient experience in a clinical trial could be different than real-life experiences, but at least Ocular Therapeutix can use this survey during its initial interactions with doctors to convince them to try Dextenza.

A report of positive patient experience probably doesn't justify the share price increase over the last few days. Last month shares were trading higher than they currently are without any news to justify the decline, so the recent increase may have more to do with momentum than the actual data.

10 stocks we like better than Ocular Therapeutix
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Ocular Therapeutix wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 6, 2017

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 4008484, ~/Articles/ArticleHandler.aspx, 3/27/2017 2:25:34 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
Change down DOW 20548.9 -47.9 -0.2%
Change down S&P 500 2338.5 -5.5 -0.2%
Change up NASD 5836.4 7.7 0.1%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

3/27/2017 2:09 PM
OCUL $9.42 Up +0.15 +1.62%
Ocular Therapeutix CAPS Rating: ***